Formation of gadolinium-ferritin from clinical magnetic resonance contrast agents
Gadolinium deposition in the brain following administration of gadolinium-based contrast agents (GBCAs) has led to health concerns. We show that some clinical GBCAs form Gd 3+ -ferritin nanoparticles at (sub)nanomolar concentrations of Gd 3+ under physiological conditions. We describe their structur...
Gespeichert in:
| Veröffentlicht in: | Nanoscale advances 2020-12, Vol.2 (12), p.5567-5571 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5571 |
|---|---|
| container_issue | 12 |
| container_start_page | 5567 |
| container_title | Nanoscale advances |
| container_volume | 2 |
| creator | Neburkova, Jitka Rulseh, Aaron M Chang, Shery L. Y Raabova, Helena Vejpravova, Jana Dracinsky, Martin Tarabek, Jan Kotek, Jan Pingle, Mohan Majer, Pavel Vymazal, Josef Cigler, Petr |
| description | Gadolinium deposition in the brain following administration of gadolinium-based contrast agents (GBCAs) has led to health concerns. We show that some clinical GBCAs form Gd
3+
-ferritin nanoparticles at (sub)nanomolar concentrations of Gd
3+
under physiological conditions. We describe their structure at atomic resolution and discuss potential relevance for clinical MRI.
We show that clinical gadolinium-based contrast agents can form Gd
3+
-ferritin nanoparticles under physiological conditions. We suggest they can contribute to the T
1
intensity changes in ferritin-rich brain areas observed in patients examined by MRI. |
| doi_str_mv | 10.1039/c9na00567f |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9417687</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2716932898</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-9de17298d9dd070489523b9f36290b5f853f235de425414c932b0516f0d631713</originalsourceid><addsrcrecordid>eNpVkU1LAzEQhoMottRevCt7FGF18rGbzUWQYlUQRdBzSLNJjewmNdkK_nu3ttZ6mmHm4Z2PF6FjDBcYqLjUwiuAouR2Dw1JgcscCIX9nXyAxim9AwDBjDEuDtGAlpjSipMhep6G2KrOBZ8Fm81VHRrn3bLNrYnRdc5nNoY206uqVk3Wqrk3ndNZNCl45bXJdPBdVKnL1Nz4Lh2hA6uaZMabOEKv05uXyV3-8HR7P7l-yDUD6HJRG8yJqGpR18CBVaIgdCYsLYmAWWGrglpCi9owUjDMtKBkBv1JFuqSYo7pCF2tdRfLWWtqbVZbNHIRXavilwzKyf8d797kPHxKwTAvK94LnG0EYvhYmtTJ1iVtmkZ5E5ZJEo7Lfmolqh49X6M6hpSisdsxGOTKBjkRj9c_Nkx7-HR3sS36-_QeOFkDMelt989H-g1PVoz_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2716932898</pqid></control><display><type>article</type><title>Formation of gadolinium-ferritin from clinical magnetic resonance contrast agents</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Neburkova, Jitka ; Rulseh, Aaron M ; Chang, Shery L. Y ; Raabova, Helena ; Vejpravova, Jana ; Dracinsky, Martin ; Tarabek, Jan ; Kotek, Jan ; Pingle, Mohan ; Majer, Pavel ; Vymazal, Josef ; Cigler, Petr</creator><creatorcontrib>Neburkova, Jitka ; Rulseh, Aaron M ; Chang, Shery L. Y ; Raabova, Helena ; Vejpravova, Jana ; Dracinsky, Martin ; Tarabek, Jan ; Kotek, Jan ; Pingle, Mohan ; Majer, Pavel ; Vymazal, Josef ; Cigler, Petr</creatorcontrib><description>Gadolinium deposition in the brain following administration of gadolinium-based contrast agents (GBCAs) has led to health concerns. We show that some clinical GBCAs form Gd
3+
-ferritin nanoparticles at (sub)nanomolar concentrations of Gd
3+
under physiological conditions. We describe their structure at atomic resolution and discuss potential relevance for clinical MRI.
We show that clinical gadolinium-based contrast agents can form Gd
3+
-ferritin nanoparticles under physiological conditions. We suggest they can contribute to the T
1
intensity changes in ferritin-rich brain areas observed in patients examined by MRI.</description><identifier>ISSN: 2516-0230</identifier><identifier>EISSN: 2516-0230</identifier><identifier>DOI: 10.1039/c9na00567f</identifier><identifier>PMID: 36133872</identifier><language>eng</language><publisher>England: RSC</publisher><subject>Chemistry</subject><ispartof>Nanoscale advances, 2020-12, Vol.2 (12), p.5567-5571</ispartof><rights>This journal is © The Royal Society of Chemistry.</rights><rights>This journal is © The Royal Society of Chemistry 2020 RSC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-9de17298d9dd070489523b9f36290b5f853f235de425414c932b0516f0d631713</citedby><cites>FETCH-LOGICAL-c400t-9de17298d9dd070489523b9f36290b5f853f235de425414c932b0516f0d631713</cites><orcidid>0000-0002-6308-9992 ; 0000-0002-8332-4419 ; 0000-0002-4495-0070 ; 0000-0003-0116-3824 ; 0000-0002-2528-3751 ; 0000-0002-1221-8619 ; 0000-0001-7514-4584 ; 0000-0003-0283-647X ; 0000-0003-1777-729X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417687/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417687/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36133872$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Neburkova, Jitka</creatorcontrib><creatorcontrib>Rulseh, Aaron M</creatorcontrib><creatorcontrib>Chang, Shery L. Y</creatorcontrib><creatorcontrib>Raabova, Helena</creatorcontrib><creatorcontrib>Vejpravova, Jana</creatorcontrib><creatorcontrib>Dracinsky, Martin</creatorcontrib><creatorcontrib>Tarabek, Jan</creatorcontrib><creatorcontrib>Kotek, Jan</creatorcontrib><creatorcontrib>Pingle, Mohan</creatorcontrib><creatorcontrib>Majer, Pavel</creatorcontrib><creatorcontrib>Vymazal, Josef</creatorcontrib><creatorcontrib>Cigler, Petr</creatorcontrib><title>Formation of gadolinium-ferritin from clinical magnetic resonance contrast agents</title><title>Nanoscale advances</title><addtitle>Nanoscale Adv</addtitle><description>Gadolinium deposition in the brain following administration of gadolinium-based contrast agents (GBCAs) has led to health concerns. We show that some clinical GBCAs form Gd
3+
-ferritin nanoparticles at (sub)nanomolar concentrations of Gd
3+
under physiological conditions. We describe their structure at atomic resolution and discuss potential relevance for clinical MRI.
We show that clinical gadolinium-based contrast agents can form Gd
3+
-ferritin nanoparticles under physiological conditions. We suggest they can contribute to the T
1
intensity changes in ferritin-rich brain areas observed in patients examined by MRI.</description><subject>Chemistry</subject><issn>2516-0230</issn><issn>2516-0230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVkU1LAzEQhoMottRevCt7FGF18rGbzUWQYlUQRdBzSLNJjewmNdkK_nu3ttZ6mmHm4Z2PF6FjDBcYqLjUwiuAouR2Dw1JgcscCIX9nXyAxim9AwDBjDEuDtGAlpjSipMhep6G2KrOBZ8Fm81VHRrn3bLNrYnRdc5nNoY206uqVk3Wqrk3ndNZNCl45bXJdPBdVKnL1Nz4Lh2hA6uaZMabOEKv05uXyV3-8HR7P7l-yDUD6HJRG8yJqGpR18CBVaIgdCYsLYmAWWGrglpCi9owUjDMtKBkBv1JFuqSYo7pCF2tdRfLWWtqbVZbNHIRXavilwzKyf8d797kPHxKwTAvK94LnG0EYvhYmtTJ1iVtmkZ5E5ZJEo7Lfmolqh49X6M6hpSisdsxGOTKBjkRj9c_Nkx7-HR3sS36-_QeOFkDMelt989H-g1PVoz_</recordid><startdate>20201215</startdate><enddate>20201215</enddate><creator>Neburkova, Jitka</creator><creator>Rulseh, Aaron M</creator><creator>Chang, Shery L. Y</creator><creator>Raabova, Helena</creator><creator>Vejpravova, Jana</creator><creator>Dracinsky, Martin</creator><creator>Tarabek, Jan</creator><creator>Kotek, Jan</creator><creator>Pingle, Mohan</creator><creator>Majer, Pavel</creator><creator>Vymazal, Josef</creator><creator>Cigler, Petr</creator><general>RSC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6308-9992</orcidid><orcidid>https://orcid.org/0000-0002-8332-4419</orcidid><orcidid>https://orcid.org/0000-0002-4495-0070</orcidid><orcidid>https://orcid.org/0000-0003-0116-3824</orcidid><orcidid>https://orcid.org/0000-0002-2528-3751</orcidid><orcidid>https://orcid.org/0000-0002-1221-8619</orcidid><orcidid>https://orcid.org/0000-0001-7514-4584</orcidid><orcidid>https://orcid.org/0000-0003-0283-647X</orcidid><orcidid>https://orcid.org/0000-0003-1777-729X</orcidid></search><sort><creationdate>20201215</creationdate><title>Formation of gadolinium-ferritin from clinical magnetic resonance contrast agents</title><author>Neburkova, Jitka ; Rulseh, Aaron M ; Chang, Shery L. Y ; Raabova, Helena ; Vejpravova, Jana ; Dracinsky, Martin ; Tarabek, Jan ; Kotek, Jan ; Pingle, Mohan ; Majer, Pavel ; Vymazal, Josef ; Cigler, Petr</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-9de17298d9dd070489523b9f36290b5f853f235de425414c932b0516f0d631713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Neburkova, Jitka</creatorcontrib><creatorcontrib>Rulseh, Aaron M</creatorcontrib><creatorcontrib>Chang, Shery L. Y</creatorcontrib><creatorcontrib>Raabova, Helena</creatorcontrib><creatorcontrib>Vejpravova, Jana</creatorcontrib><creatorcontrib>Dracinsky, Martin</creatorcontrib><creatorcontrib>Tarabek, Jan</creatorcontrib><creatorcontrib>Kotek, Jan</creatorcontrib><creatorcontrib>Pingle, Mohan</creatorcontrib><creatorcontrib>Majer, Pavel</creatorcontrib><creatorcontrib>Vymazal, Josef</creatorcontrib><creatorcontrib>Cigler, Petr</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nanoscale advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Neburkova, Jitka</au><au>Rulseh, Aaron M</au><au>Chang, Shery L. Y</au><au>Raabova, Helena</au><au>Vejpravova, Jana</au><au>Dracinsky, Martin</au><au>Tarabek, Jan</au><au>Kotek, Jan</au><au>Pingle, Mohan</au><au>Majer, Pavel</au><au>Vymazal, Josef</au><au>Cigler, Petr</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Formation of gadolinium-ferritin from clinical magnetic resonance contrast agents</atitle><jtitle>Nanoscale advances</jtitle><addtitle>Nanoscale Adv</addtitle><date>2020-12-15</date><risdate>2020</risdate><volume>2</volume><issue>12</issue><spage>5567</spage><epage>5571</epage><pages>5567-5571</pages><issn>2516-0230</issn><eissn>2516-0230</eissn><abstract>Gadolinium deposition in the brain following administration of gadolinium-based contrast agents (GBCAs) has led to health concerns. We show that some clinical GBCAs form Gd
3+
-ferritin nanoparticles at (sub)nanomolar concentrations of Gd
3+
under physiological conditions. We describe their structure at atomic resolution and discuss potential relevance for clinical MRI.
We show that clinical gadolinium-based contrast agents can form Gd
3+
-ferritin nanoparticles under physiological conditions. We suggest they can contribute to the T
1
intensity changes in ferritin-rich brain areas observed in patients examined by MRI.</abstract><cop>England</cop><pub>RSC</pub><pmid>36133872</pmid><doi>10.1039/c9na00567f</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-6308-9992</orcidid><orcidid>https://orcid.org/0000-0002-8332-4419</orcidid><orcidid>https://orcid.org/0000-0002-4495-0070</orcidid><orcidid>https://orcid.org/0000-0003-0116-3824</orcidid><orcidid>https://orcid.org/0000-0002-2528-3751</orcidid><orcidid>https://orcid.org/0000-0002-1221-8619</orcidid><orcidid>https://orcid.org/0000-0001-7514-4584</orcidid><orcidid>https://orcid.org/0000-0003-0283-647X</orcidid><orcidid>https://orcid.org/0000-0003-1777-729X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2516-0230 |
| ispartof | Nanoscale advances, 2020-12, Vol.2 (12), p.5567-5571 |
| issn | 2516-0230 2516-0230 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9417687 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Chemistry |
| title | Formation of gadolinium-ferritin from clinical magnetic resonance contrast agents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T07%3A04%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Formation%20of%20gadolinium-ferritin%20from%20clinical%20magnetic%20resonance%20contrast%20agents&rft.jtitle=Nanoscale%20advances&rft.au=Neburkova,%20Jitka&rft.date=2020-12-15&rft.volume=2&rft.issue=12&rft.spage=5567&rft.epage=5571&rft.pages=5567-5571&rft.issn=2516-0230&rft.eissn=2516-0230&rft_id=info:doi/10.1039/c9na00567f&rft_dat=%3Cproquest_pubme%3E2716932898%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2716932898&rft_id=info:pmid/36133872&rfr_iscdi=true |